Overlooked Prophylaxis of Hepatitis B in PatientsUndergoing Hematopoietic Stem Cell Transplantation

TÜRE, Zeynep Ture; kahveci, hüseyin nadir; KEKLİK, Muzaffer; KALIN ÜNÜVAR, Gamze; ULU KILIÇ, Ayşegül

doi:10.14744/etd.2020.36786

Overlooked Prophylaxis of Hepatitis B in PatientsUndergoing Hematopoietic Stem Cell Transplantation

Zeynep TÜRE, (Erciyes Üniversitesi, Tıp Fakültesi, Bulaşıcı Hastalıklar Bölümü, Kayseri, Türkiye)

Gamze Kalın ÜNÜVAR, (Erciyes Üniversitesi, Tıp Fakültesi, Bulaşıcı Hastalıklar Bölümü, Kayseri, Türkiye)

Hüseyin Nadir KAHVECİ, (Erciyes Üniversitesi, Tıp Fakültesi, Bulaşıcı Hastalıklar Bölümü, Kayseri, Türkiye)

Muzaffer KEKLİK, (Erciyes Üniversitesi, Hematoloji Anabilim Dalı, Kayseri, Türkiye)

Ayşegül Ulu KILIÇ (Erciyes Üniversitesi, Tıp Fakültesi, Bulaşıcı Hastalıklar Bölümü, Kayseri, Türkiye)

Erciyes Medical Journal

1 1

Yıl: 2021 Cilt: 43 Sayı: 1 Sayfa Aralığı: 31 - 36 Metin Dili: İngilizce DOI: 10.14744/etd.2020.36786 İndeks Tarihi: 27-01-2022

Overlooked Prophylaxis of Hepatitis B in PatientsUndergoing Hematopoietic Stem Cell Transplantation

Öz:

Objective: The reactivation rate of dormant hepatitis B virus (HBV) in the liver is between 4.1% and 41.5% in immune-com promised patients. The disappearance of hepatitis B surface antibody (anti-HBs) can be an alarm for hepatitis B reactivation.In this study, the changes in serological status, reactivation rates, and antiviral prophylaxis rates were evaluated. Materials and Methods: A retrospective study was conducted involving patients who were followed up at Erciyes Univer sity HSCT Center between January 2018 and July 2019. The demographic data, type of hematological disease, pre- andpost-transplant status of HBV, presence of antiviral prophylaxis, and frequency of hepatitis B flare were evaluated. Results: One hundred and seven patients were included in this study. The median follow-up duration was 18 months. Newchemotherapy protocols were initiated in 36 patients due to progression and in 23 patients with a diagnosis of graft-versus host disease. Anti-HBs levels decreased in 60% of the patients, and anti-HBs levels decreased to below the protective levelin 13% of the patients. Among the 107 patients, 38 had resolved hepatitis B infection before transplantation, and 20 andfour of 18 patients (22%) who did not receive antiviral prophylaxis developed HBV seroconversion and hepatitis B flare. Themedian levels of anti-HBs titers after transplantation were 167 IU/L and 15 IU/L in groups that received and did not receiveantiviral prophylaxis, respectively (p=0.028). Conclusion: Antiviral prophylaxis should be administered in patients positive for hepatitis B core antibody before hemato poietic stem-cell transplantation. Measuring HBV serological parameters at regular intervals is essential in the high-risk group.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Varma A, Biritxinaga L, Saliba RM, Stich M, Jauch SF, Afrough A, et al. Impact of Hepatitis B Core Antibody Seropositivity on the Outcome of Autologous ematopoietic Stem Cell Transplantation for Multiple My-eloma. Biol Blood Marrow Transplant 2017; 23(4):581–7.
2. Tosun S. The Changing Viral Hepatitis Epidemiology in our Country. ANKEM Derg 2013; 27(Ek 2): 128–34.
3. Onozawa M, Hashino S, Izumiyama K, Kahata K, Chuma M, Mori A, et al. Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection. Transplantation 2005; 79(5): 616–9.
4. Singh D, Hassan M, Lim N. Reactivation of Hepatitis B Virus Infection With Reverse Seroconversion Following Umbilical Cord Allogeneic Hematopoietic Cell Transplantation in a Hepatitis-B-Immune Patient: A Case Report. Transplant Proc 2019; 51(2): 602–4.
5. Kusumoto S, Arcaini L, Hong X, Jin J, Kim WS, Kwong YL, et al. Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy. Blood 2019; 133(2): 137–46.
6. Mikulska M, Nicolini L, Signori A, Rivoli G, Del Bono V, Raiola AM, et al. Hepatitis B reactivation in HBsAg-negative/HBcAb-positive allogeneic haematopoietic stem cell transplant recipients: risk factors and outcome. Clin Microbiol Infect 2014; 20(10): O694-701.
7. Pawłowska M, Flisiak R, Gil L, Horban A, Hus I, Jaroszewicz J, et al. Prophylaxis of hepatitis B virus (HBV) infection reactivation - recommendations of the Working Group for prevention of HBV reactivation. Clin Exp Hepatol 2019; 5(3): 195–202.
8. Sarmati L, Andreoni M, Antonelli G, Arcese W, Bruno R, Coppola N, et al. Recommendations for screening, monitoring, prevention, prophylaxis and therapy of hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation-a position paper. Clin Microbiol Infect. 2017; 23(12): 935–40.
9. Uhm JE, Kim K, Lim TK, Park BB, Park S, Hong YS, et al. Changes in serologic markers of hepatitis B following autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007; 13(4): 463–8.
10. Seto WK, Chan TS, Hwang YY, Wong DK, Fung J, Liu KS, et al. Hepatitis B reactivation in occult viral carriers undergoing hematopoietic stem cell transplantation: A prospective study. Hepatology 2017; 65(5): 1451–61.
11. Çeneli Ö, Özkurt ZN, Acar K, Rota S, Aki ŞZ, Yeğin ZA, et al. Hepatitis B-related events in autologous hematopoietic stem cell transplantation recipients. World J Gastroenterol 2010; 16(14): 1765–71.
12. Gentile G, Andreoni M, Antonelli G, Sarmati L. Screening, monitoring, prevention, prophylaxis and therapy for hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation: a systematic review. Clin Microbiol Infect 2017; 23(12): 916–23.
13. Özkan H. Epidemiology of Chronic Hepatitis B in Turkey. Euroasian J Hepatogastroenterol 2018; 8(1): 73–4.
14. Park H, Kim DY, Kim SJ, Chung H, Cho H, Jang JE, et al. HBsAg-Negative, Anti-HBc-Negative Patients Still Have a Risk of Hepatitis B Virus-Related Hepatitis after Autologous Stem Cell Transplantation for Multiple Myeloma or Malignant Lymphoma. Cancer Res Treat 2018; 50(4): 1121–9.
15. Han JW, Yang H, Lee HL, Bae SH, Choi JY, Lee JW, et al. Risk factors and outcomes of hepatitis B virus reactivation in hepatitis B surface antigen negative patients with hematological malignancies. Hepatol Res 2016; 46(7): 657–68.
16. Teh BW, Slavin MA, Szer J, Sasadeusz JJ. Hepatitis B serological changes following allogeneic bone marrow transplantation.Transpl Infect Dis 2013; 15(1): 98–103.
17. EASL. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. European Association For The Study Of The Liver. J Hepatol 2012; 57(1): 167–85.
18. Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int 2016; 10(1): 1–98.
19. Anastasiou OE, Almpani F, Herrmann A, Gerken G, Ditschkowski M, Ciesek S. HBV reactivation in allogeneic stem cell transplant recipients: Risk factors, outcome, and role of hepatitis B virus mutations. Hepatol Commun 2017; 1(10): 1014–23

APA	TÜRE Z, KALIN ÜNÜVAR G, kahveci h, KEKLİK M, ULU KILIÇ A (2021). Overlooked Prophylaxis of Hepatitis B in PatientsUndergoing Hematopoietic Stem Cell Transplantation. , 31 - 36. 10.14744/etd.2020.36786
Chicago	TÜRE Zeynep Ture,KALIN ÜNÜVAR Gamze,kahveci hüseyin nadir,KEKLİK Muzaffer,ULU KILIÇ Ayşegül Overlooked Prophylaxis of Hepatitis B in PatientsUndergoing Hematopoietic Stem Cell Transplantation. (2021): 31 - 36. 10.14744/etd.2020.36786
MLA	TÜRE Zeynep Ture,KALIN ÜNÜVAR Gamze,kahveci hüseyin nadir,KEKLİK Muzaffer,ULU KILIÇ Ayşegül Overlooked Prophylaxis of Hepatitis B in PatientsUndergoing Hematopoietic Stem Cell Transplantation. , 2021, ss.31 - 36. 10.14744/etd.2020.36786
AMA	TÜRE Z,KALIN ÜNÜVAR G,kahveci h,KEKLİK M,ULU KILIÇ A Overlooked Prophylaxis of Hepatitis B in PatientsUndergoing Hematopoietic Stem Cell Transplantation. . 2021; 31 - 36. 10.14744/etd.2020.36786
Vancouver	TÜRE Z,KALIN ÜNÜVAR G,kahveci h,KEKLİK M,ULU KILIÇ A Overlooked Prophylaxis of Hepatitis B in PatientsUndergoing Hematopoietic Stem Cell Transplantation. . 2021; 31 - 36. 10.14744/etd.2020.36786
IEEE	TÜRE Z,KALIN ÜNÜVAR G,kahveci h,KEKLİK M,ULU KILIÇ A "Overlooked Prophylaxis of Hepatitis B in PatientsUndergoing Hematopoietic Stem Cell Transplantation." , ss.31 - 36, 2021. 10.14744/etd.2020.36786
ISNAD	TÜRE, Zeynep Ture vd. "Overlooked Prophylaxis of Hepatitis B in PatientsUndergoing Hematopoietic Stem Cell Transplantation". (2021), 31-36. https://doi.org/10.14744/etd.2020.36786

APA	TÜRE Z, KALIN ÜNÜVAR G, kahveci h, KEKLİK M, ULU KILIÇ A (2021). Overlooked Prophylaxis of Hepatitis B in PatientsUndergoing Hematopoietic Stem Cell Transplantation. Erciyes Medical Journal, 43(1), 31 - 36. 10.14744/etd.2020.36786
Chicago	TÜRE Zeynep Ture,KALIN ÜNÜVAR Gamze,kahveci hüseyin nadir,KEKLİK Muzaffer,ULU KILIÇ Ayşegül Overlooked Prophylaxis of Hepatitis B in PatientsUndergoing Hematopoietic Stem Cell Transplantation. Erciyes Medical Journal 43, no.1 (2021): 31 - 36. 10.14744/etd.2020.36786
MLA	TÜRE Zeynep Ture,KALIN ÜNÜVAR Gamze,kahveci hüseyin nadir,KEKLİK Muzaffer,ULU KILIÇ Ayşegül Overlooked Prophylaxis of Hepatitis B in PatientsUndergoing Hematopoietic Stem Cell Transplantation. Erciyes Medical Journal, vol.43, no.1, 2021, ss.31 - 36. 10.14744/etd.2020.36786
AMA	TÜRE Z,KALIN ÜNÜVAR G,kahveci h,KEKLİK M,ULU KILIÇ A Overlooked Prophylaxis of Hepatitis B in PatientsUndergoing Hematopoietic Stem Cell Transplantation. Erciyes Medical Journal. 2021; 43(1): 31 - 36. 10.14744/etd.2020.36786
Vancouver	TÜRE Z,KALIN ÜNÜVAR G,kahveci h,KEKLİK M,ULU KILIÇ A Overlooked Prophylaxis of Hepatitis B in PatientsUndergoing Hematopoietic Stem Cell Transplantation. Erciyes Medical Journal. 2021; 43(1): 31 - 36. 10.14744/etd.2020.36786
IEEE	TÜRE Z,KALIN ÜNÜVAR G,kahveci h,KEKLİK M,ULU KILIÇ A "Overlooked Prophylaxis of Hepatitis B in PatientsUndergoing Hematopoietic Stem Cell Transplantation." Erciyes Medical Journal, 43, ss.31 - 36, 2021. 10.14744/etd.2020.36786
ISNAD	TÜRE, Zeynep Ture vd. "Overlooked Prophylaxis of Hepatitis B in PatientsUndergoing Hematopoietic Stem Cell Transplantation". Erciyes Medical Journal 43/1 (2021), 31-36. https://doi.org/10.14744/etd.2020.36786